Mobile UPI  |   About UPI  |   UPI en Español  |   UPI Arabic  |   UPIU  |   My Account
Search:
Go

Health News

No lucky surprise on Genentech drug

Oct. 20, 2008
Genentech shareholders hoping for a quick boost from a closely watched clinical trial will have to wait until next year to find out whether the biotechnology giant's drug Avastin protects patients from a recurrence of colon cancer after surgery. Experts who...
Related Stories from UPI.com

Study says Avastin needs black box warning

NEW YORK, Nov. 19 (UPI) -- A drug touted as a safer, gentler way to treat cancer increases the risk of blood clots, a U.S. study in the Journal of the American Medical Association said.

Genentech says 'no' to Roche

SOUTH SAN FRANCISCO, Calif., Aug. 14 (UPI) -- Swiss pharmaceutical behemoth Roche will have to dig deeper into its pockets if it wants to own all of Genentech Inc., which rejected its $43.7 billion offer.

Roche to buy rest of Genentech

BASEL, Switzerland, July 21 (UPI) -- Swiss drugmaker Roche Holding AG has offered $43.7 billion -- $89 a share -- for the U.S. biotech firm Genentech.

Use of expensive cancer drugs questioned

NEW YORK, July 6 (UPI) -- The cancer medication Avastin has been called a wonder drug, but may be less effective than U.S. regulators believed when they approved it.

Drug therapy benefits diabetic eye disease

NEW YORK, April 30 (UPI) -- U.S. scientists say a new drug designed to treat diabetic eye disease performed better in clinical trials than did the current standard of laser surgery.

High-priced drugs raising questions

NEW YORK, March 16 (UPI) -- Some researchers are questioning the ethics of prescribing higher-than-necessary doses of high-priced drugs in the United States.

FDA approves Avastin for breast cancer

SAN FRANCISCO, Feb. 22 (UPI) -- The U.S. Food and Drug Administration has granted accelerated approval for Avastin in combination with paclitaxel chemotherapy for treatment of breast cancer.

Bevacizumab slows metastatic breast cancer

CHICAGO, Dec. 27 (UPI) -- Bevacizumab, a drug which slows tumor-supporting blood vessels, added to standard chemotherapy slowed metastatic breast cancer, a U.S. clinical trial found.

Avastin shows promise in brain cancer

DETROIT, Dec. 14 (UPI) -- A clinical study in Michigan found that brain cancer patients treated with the drug Avastin are living longer without further progression of the disease.

EU approves Avastin for lung cancer

BASAL, Switzerland, Aug. 24 (UPI) -- The European Union has approved the anti-cancer drug Avastin as a first-line treatment for advanced lung cancer.

Cancer drug helps save vision

NEW YORK, June 22 (UPI) -- A U.S. study says patients with radiation retinopathy can keep their eyesight longer by using the cancer drug Avastin.

Herceptin shown useful for more patients

CHICAGO, June 12 (UPI) -- U.S. researchers say the breast cancer drug Herceptin is not reaching many of the women who could benefit from it.

FDA orders warnings for Xolair

WASHINGTON, Feb. 21 (UPI) -- The U.S. Food and Drug Administration ordered Genentech Inc. to add a boxed warning to its asthmatic drug marketed as Xolair.

Genentech buys Amphora's oncology program

LOS ALTOS, Calif., Jan. 9 (UPI) -- U.S. firm Amphora Discovery Corporation said Tuesday Genentech agreed to purchase its oncology program for an undisclosed sum.

Avastin extends lung cancer survivability

BASEL, Switzerland, Dec. 14 (UPI) -- The drug Avastin has become the first medicine proven to help patients suffering from the most common form of lung cancer to live longer than a year.
1 of 28
Lori Anne Madison, 6, competes in Scripps National Spelling Bee
View Caption
Lori Anne Madison, 6, of Woodbridge, Virginia, spells out the letters in her word as she competes during the opening round of the Scripps National Spelling Bee, May 30, 2012, in National Harbor, Maryland. Madison, the youngest known qualifier in the history of the contest, correctly spelled the word "dirigible*", a lighter-than-air aircraft, to advance. UPI/Mike Theiler